Vistin Pharma ASA (VISTN): Mandatory notification of trade and disclosure of large shareholding
Vistin Pharma ASA (VISTN) · publisert 6. mai 2025 kl. 15:03 · vis på NewsWeb
Transaksjoner
| Person | Rolle | Type | Volum | Pris | Dato | ISIN | Handelsplass |
|---|---|---|---|---|---|---|---|
| Øystein Stray Spetalen via Ferncliff Listed Dai AS | Styremedlem | Salg | 1 234 280 | 22,5 NOK | 6. mai 2025 | NO0010734122 | Oslo Stock Exchange, MIC: XOSL |
| Øyvin Brøymer via Intertrade Shipping AS | Styreleder | Kjøp | 1 934 280 | 22,5 NOK | 6. mai 2025 | NO0010734122 | Oslo Stock Exchange, MIC: XOSL |
| Øystein Stray Spetalen via Saga Pure ASA | Styremedlem | Salg | 700 000 | 22,5 NOK | 6. mai 2025 | NO0010734122 | Oslo Stock Exchange, MIC: XOSL |
Vedlegg
- 20250506_Notification of trade_Saga.pdf (application/pdf, originaldokument)
- 20250506_Notification of trade_Ferncliff Listed Dai.pdf (application/pdf, originaldokument)
- 06052025_Notification of trade_Intertrade Shipping AS.pdf (application/pdf, originaldokument)
Meldingstekst
Ferncliff Listed Dai AS has on 6 May 2025 sold 1,234,280 shares in Vistin Pharma
ASA at NOK 22.50 per share.
Saga Pure ASA has on 6 May 2025 sold 700,000 shares in Vistin Pharma ASA at NOK
22.50 per share.
After the transaction Saga Pure ASA and Ferncliff Listed Dai AS has no holding
of shares in Vistin Pharma ASA. Øystein Stray Spetalen and associated parties
have a holding of 331,886 shares in Vistin Pharma ASA.
Saga Pure ASA and Ferncliff Listed Dai AS are closely associated with board
member Øystein Stray Spetalen.
The ownerhip by Øystein Stray Spetalen and associated companies have after these
transactions surpassed below ownership of 5%.
At the same time Intertrade Shipping AS, closely associated with Chairman Øyvin
A. Brøymer, has purchased 1 934 280 shares, equal to the number of shares sold
by Ferncliff Listed Dai AS and Saga Pure ASA, at a price of NOK 22.50 per share.
After this transaction Intertrade Shipping AS holds a total number of
14 509 280 shares, equal to 32,72% of the shares in Vistin Pharma ASA.
Please see the attached notification forms.
This information is subject to the disclosure requirements pursuant to Section
5-12 the Norwegian Securities Trading Act